DOCSLIB.ORG

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial Study Protocol Supported by The National Institute of Neurological Disorders and Stroke (NINDS) Principal Investigator S. Claiborne Johnston, MD, PhD Professor of Neurology and Epidemiology University of California San Francisco Co-Principal Investigator J. Donald Easton, MD Clinical Professor of Neurology University of California San Francisco Protocol Version 5.1 – United Kingdom Specific NCT00991029 EudraCT 2013-001185-41 POINT Trial Protocol INVESTIGATOR PROTOCOL SIGNATURE PAGE Protocol Version (____) dated (_____) I have read this protocol and agree to adhere to the requirements. I will provide copies of this protocol and all pertinent information to the study personnel under my supervision. I will discuss this material with them and ensure they are fully informed regarding the investigational plan and the conduct of the study, applicable laws, regulations, international standards, and ethical and safety considerations, including 21 CFR Parts 50, 54 and 56, International Conference on Harmonization (ICH) Good Clinical Practices (GCP) Guidelines, and Institutional Review Board (IRB) or Ethics Committee (EC) requirements. _____________________________________ ________________ Clinical Site Date _____________________________________ ________________ Site Principal Investigator Signature Date _____________________________________ ________________ Site Principal Investigator Printed Name Date Ve rsion 5.1 Amended UK s pe cifi c December 2, 2013 Pa ge 2 POINT Trial Protocol COUNTRY COORDINATOR PROTOCOL SIGNATURE PAGE Protocol Version (____) dated (_____) I have read this protocol and agree to adhere to the requirements. I will provide copies of this protocol and all pertinent information to the study personnel under my supervision. I will discuss this material with them and ensure they are fully informed regarding the investigational plan and the conduct of the study, applicable laws, regulations, international standards, and ethical and safety considerations, including 21 CFR Parts 50, 54 and 56, International Conference on Harmonization (ICH) Good Clinical Practices (GCP) Guidelines, and Institutional Review Board (IRB) or Ethics Committee (EC) requirements. _____________________________________ ________________ Country/Clinical Site Date _____________________________________ ________________ Country Coordinator Signature Date _____________________________________ ________________ Country Coordinator Printed Name Date Ve rsion 5.1 Amended UK s pe cifi c December 2, 2013 Pa ge 3 POINT Trial Protocol Table of Contents INVESTIGATOR PROTOCOL SIGNATURE PAGE..................................................................................... 2 COUNTRY COORDINATOR PROTOCOL SIGNATURE PAGE..................................................................... 3 Table of Contents ............................................................................................................................. 4 POINT PROTOCOL SYNOPSIS ............................................................................................................. 8 1 STUDY FLOWCHARTS ............................................................................................................... 12 1.1 Graphical Study Design .................................................................................................... 12 1.2 Schedule of Activities and Assessments ............................................................................ 13 2 BACKGROUND AND SIGNIFICANCE ........................................................................................... 14 2.1 TIA Incidence .................................................................................................................. 15 2.2 Short-term Prognosis....................................................................................................... 15 2.3 Underlying Pathophysiology of TIA and Minor Ischemic Stroke .......................................... 17 2.4 Potential Therapies ......................................................................................................... 17 2.4.1 Aspirin......................................................................................................................... 18 2.4.2 Clopidogrel .................................................................................................................. 18 2.4.3 Combination Clopidogrel-Aspirin .................................................................................. 19 2.4.4 Dipyridamole ............................................................................................................... 22 2.5 Advantages of a TIA Acute Treatment Trial ....................................................................... 22 2.6 Preliminary Studies.......................................................................................................... 22 2.6.1 Predictors of Stroke Risk after TIA ................................................................................. 23 2.6.2 Importance of Recovery: Risk of Stroke after Recovery in NINDS tPA, TOAST Trials ......... 24 2.6.3 Current Utilization of Antithrombotics after TIA ......................................................... 24 3 STUDY OBJECTIVES .................................................................................................................. 25 3.1 Secondary ....................................................................................................................... 25 4 STUDY DESIGN AND MANAGEMENT OVERVIEW ........................................................................ 25 4.1 Study Design Overview .................................................................................................... 25 4.2 Study Milestones............................................................................................................. 26 4.3 Organizational Structure and Communication Flow ........................................................... 26 4.3.1 Trial Organization ........................................................................................................ 28 Ve rsion 5.1 Amended UK s pe cifi c December 2, 2013 Pa ge 4 POINT Trial Protocol 4.4 Site Training, Certification, and Update............................................................................. 28 4.5 Contact Schedule and Measurements............................................................................... 29 4.6 Outcomes ....................................................................................................................... 29 4.6.1 Definitions of Clinical Outcomes/Serious Adverse Events ............................................... 29 5 PARTICIPANT SELECTION ......................................................................................................... 32 5.1 Study Population ............................................................................................................. 32 5.2 Inclusion and Exclusion Criteria ........................................................................................ 33 6 TREATMENTS .......................................................................................................................... 34 6.1 Study Drugs .................................................................................................................... 34 6.2 Assignment to a Treatment Group.................................................................................... 35 7 STUDY DRUG HANDLING.......................................................................................................... 35 7.1 Supply and Storage.......................................................................................................... 35 7.2 Packaging........................................................................................................................ 36 7.3 Responsibilities ............................................................................................................... 36 7.4 Concurrent Treatment ..................................................................................................... 37 7.4.1 Prohibited Concomitant Treatments ............................................................................. 37 7.4.2 Permitted Concurrent Treatments ................................................................................ 37 7.5 Treatment Discontinuation .............................................................................................. 38 7.5.1 Permanent Treatment Discontinuation ......................................................................... 38 7.6 Blinding System and Emergency Unblinding Procedure...................................................... 38 8 SAFETY.................................................................................................................................... 39 8.1 Protection/Minimization of Risk ....................................................................................... 39 8.2 Serious Adverse Events .................................................................................................... 40 8.2.1 Management of SAEs/Clinical Outcomes ....................................................................... 40 8.3 Definitions ...................................................................................................................... 40 8.4 Classification of Adverse Events ......................................................................................
Load more

Recommended publications
  • Effects of Remote Ischemic Pre-Conditioning on Neurologic
    Effects of Remote Ischemic Pre-Conditioning on Neurologic Complications in Adult Ischemic Moyamoya Disease Patients Undergoing Encephaloduroarteriosynangiosis（RIME） —— A Prospective, Multi-center, Randomized Controlled Trial —— Study Protocol Neurosurgical Principal Investigator Yuanli Zhao Professor of Neurosurgery Beijing Tiantan Hospital, Capital Medical University, Beijing Peking University International Hospital, Peking University, Beijing Rong Wang Professor of Neurosurgery Beijing Tiantan Hospital, Capital Medical University, Beijing Peking University International Hospital, Peking University, Beijing Xun Ye Professor of Neurosurgery Beijing Tiantan Hospital, Capital Medical University, Beijing Peking University International Hospital, Peking University, Beijing August 20, 2019 1. Protocol Synopsis Effects of Remote Ischemic Pre-Conditioning on Neurologic Complications in Adult Ischemic Moyamoya Title Disease Patients Undergoing Encephaloduroarteriosynangiosis Acronym RIME • To evaluate the safety of remote ischemic preconditioning in adult ischemic MMD patients undergoing indirect revascularization; Objectives • To evaluate the clinical benefit of remote ischemic preconditioning in adults with ischemic MMD who underwent indirect revascularization. This study was a multi-center, prospective, randomized, controlled trial of randomized (1:1) adult ischemic MMD patients undergoing indirect revascularization into two groups: 1. RIPC group Remote limb ischemic preconditioning (RIPC) is consisted of five 5-min cycles of bilateral arm
    [Show full text]
  • Hydrophilic Polymer Embolism: Implications for Manufacturing, Regulation, and Postmarket Surveillance of Coated Intravascular Medical Devices
    Clinical and Translational Science Institute Centers 3-19-2018 Hydrophilic Polymer Embolism: Implications for Manufacturing, Regulation, and Postmarket Surveillance of Coated Intravascular Medical Devices Rashi I. Mehta West Virginia University Rupal I. Mehta University of Rochester Follow this and additional works at: https://researchrepository.wvu.edu/ctsi Part of the Medicine and Health Sciences Commons Digital Commons Citation Mehta, Rashi I. and Mehta, Rupal I., "Hydrophilic Polymer Embolism: Implications for Manufacturing, Regulation, and Postmarket Surveillance of Coated Intravascular Medical Devices" (2018). Clinical and Translational Science Institute. 926. https://researchrepository.wvu.edu/ctsi/926 This Article is brought to you for free and open access by the Centers at The Research Repository @ WVU. It has been accepted for inclusion in Clinical and Translational Science Institute by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author J Patient Manuscript Author Saf. Author manuscript; Manuscript Author available in PMC 2019 September 19. Hydrophilic Polymer Embolism: Implications for Manufacturing, Regulation, and Postmarket Surveillance of Coated Intravascular Medical Devices Rashi I. Mehta, MD1 and Rupal I. Mehta, MD2,3,4,5,* 1West Virginia University, Department of Radiology 2University of Rochester Department of Pathology and Laboratory Medicine 3Department of Neuroscience 4Center for Neurotherapeutics Discovery (CND) 5Center for Translational Neuromedicine (CTN) Abstract Hydrophilic polymers are ubiquitously applied as surface coatings on catheters and intravascular medical technologies. Recent clinical literature has heightened awareness on the complication of hydrophilic polymer embolism (HPE), the phenomenon wherein polymer coating layers separate from catheter and device surfaces, and may be affiliated with a range of unanticipated adverse reactions.
    [Show full text]
  • Diabetic Muscle Infarction: a Rare Cause of Acute Limb Pain in Dialysis Patients
    Hindawi Publishing Corporation Case Reports in Nephrology Volume 2013, Article ID 931523, 6 pages http://dx.doi.org/10.1155/2013/931523 Case Report Diabetic Muscle Infarction: A Rare Cause of Acute Limb Pain in Dialysis Patients G. De Vlieger,1 B. Bammens,1,2 F. Claus,3 R. Vos,4 and K. Claes1,2 1 Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium 2 Laboratory of Nephrology, Department of Microbiology and Imunology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium 3 Department of Radiology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium 4 Respiratory Division, University of Leuven and Department of Clinical Respiratory Medicine, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium Correspondence should be addressed to G. De Vlieger; [email protected] Received 18 March 2013; Accepted 7 April 2013 Academic Editors: J. Almirall, P. S. Passadakis, and H. Schiffl Copyright © 2013 G. De Vlieger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Diabetic muscle infarction is a rare microangiopathic complication occurring in patients with advanced diabetes mellitus. Diabetic patients with chronic kidney disease stage Vd are prone to develop this complication. The presenting symptom is a localized painful swelling of the affected limb. Symptoms usually resolve spontaneously during the following weeks, but frequent relapse can occur and in some cases swelling may lead to compartment syndrome. Biochemical blood analyses show an elevated C-reactive protein, but creatine kinase is often normal.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,741,881 B2 Prince (45) Date of Patent: *May 25, 2004
    USOO674.1881B2 (12) United States Patent (10) Patent No.: US 6,741,881 B2 Prince (45) Date of Patent: *May 25, 2004 (54) METHOD AND APPARATUS FOR 4,202,333 A 5/1980 Thill et al. MAGNETIC RESONANCE IMAGING OF ARTERIES USING AMAGNETIC (List continued on next page.) RESONANCE CONTRASTAGENT FOREIGN PATENT DOCUMENTS (76) Inventor: Martin R. Prince, 2745 Windwood Dr., EP 543468 5/1993 Apt. 240, Ann Arbor, MI (US) 48105 WO WO 94/28781 12/1994 OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 Bolus-Enhanced Fast-3D-TOF MR Angiography of U.S.C. 154(b) by 0 days. Peripheral Vascular Occlusive Disease, Thurnher et al., Proceedings of the ISMRM, Apr. 27-May 3, 1996, vol. 2, p. This patent is Subject to a terminal dis 733. claimer. (List continued on next page.) Primary Examiner Ruth S. Smith (21) Appl. No.: 10/212,527 (74) Attorney, Agent, or Firm Neil Steinberg (22) Filed: Aug. 5, 2002 (57) ABSTRACT (65) Prior Publication Data The present invention is a technique and apparatus for US 2003/0047083 A1 Mar. 13, 2003 providing preferential enhancement of an artery of interest relative to adjacent veins and background tissue by corre Related U.S. Application Data lating the collection of a predetermined portion of data of a magnetic resonance contrast image during the arterial phase (63) Continuation of application No. 09/828,429, filed on Apr. 7, of the magnetic resonance contrast enhancement. The arte 2001, now Pat. No. 6,463,318, which is a continuation of rial phase of the contrast enhancement may be described as application No.
    [Show full text]
  • Feline Arterial Thromboembolism: Prognostic Factors and Treatment
    164 Continuing education Vlaams Diergeneeskundig Tijdschrift, 2018, 87 Feline arterial thromboembolism: prognostic factors and treatment Feliene arteriële trombo-embolie: prognostische factoren en behandeling 1L. Locquet, 1D. Paepe, 1S. Daminet, 1P. Smets 1Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium [email protected] A BSTRACT Feline arterial thromboembolism (ATE) is a complete or partial obstruction of a peripheral artery caused by a thrombus that was formed at a distant site. The most common underlying cause in cats is cardiomyopathy. Given the clinical presentation, often without preceding signs, an ATE event is considered one of the most distressing emergency conditions in feline practice. Often, these cats are euthanized at the time of diagnosis. However, recent scientific research has shown that a subpopulation of these patients may have long-term survival. In case of adequate treatment and follow-up, some cats survive over a year with a satisfying quality of life. Key points of ATE are the identification of specific prognostic factors in the individual patient in order to guide owner communication, the decision to treat or not to treat, individually adjusted patient management and regular monitoring, which are discussed in this article. SAMENVATTING Feliene arterïele trombo-embolie (ATE) wordt veroorzaakt door een volledige of gedeeltelijke ob- structie van een perifere arterie ten gevolge van trombus die gevormd werd op een andere plaats; dit vaak ten gevolge van cardiomyopathie. Gezien de klinische presentatie, waaraan vaak geen sympto- men vooraf gaan, wordt ATE beschouwd als een van de meest verontrustende, spoedeisende situaties in de praktijk. Een aanzienlijk deel van deze patiënten wordt geëuthanaseerd op het moment van di- agnose.
    [Show full text]
  • Predicting 10-Year Risk of Recurrent Cardiovascular
    IJCA-28946; No of Pages 9 International Journal of Cardiology xxx (2020) xxx Contents lists available at ScienceDirect International Journal of Cardiology journal homepage: www.elsevier.com/locate/ijcard Predicting 10-year risk of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH C.C. van 't Klooster a, D.L. Bhatt b, P.G. Steg c,k, J.M. Massaro d, J.A.N. Dorresteijn a, J. Westerink a, Y.M. Ruigrok e, G.J. de Borst f, F.W. Asselbergs g,h,i, Y. van der Graaf j, F.L.J. Visseren a,⁎, On behalf of the UCC-SMART study group a Department of Vascular Medicine, University Medical Center Utrecht (UMCU), University Utrecht, Utrecht, the Netherlands b Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA c French Alliance for Cardiovascular Trials, Hôpital Bichat, Paris, France d Department of Biostatistics Boston University School of Public Health, Boston, MA, USA e Department of Neurology and Neurosurgery, University Medical Center Utrecht (UMCU), University Utrecht, Utrecht, the Netherlands f Department of Vascular Surgery, University Medical Center Utrecht (UMCU), University Utrecht, Utrecht, the Netherlands g Department of Cardiology, Division Heart & Lungs, UMCU, Utrecht University, Utrecht, the Netherlands h Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, United Kingdom i Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom j Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), University Utrecht, Utrecht, the Netherlands k Assistance Publique-Hôpitaux de Paris, Université de Paris, INSERM Unité, 1148 Paris, France article info abstract Article history: Background: Existing cardiovascular risk scores for patients with established cardiovascular disease (CVD) esti- Received 22 June 2020 mate residual risk of recurrent major cardiovascular events (MACE).
    [Show full text]
  • The Freedom from Ischemic Events
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Harvard University - DASH The FReedom from Ischemic Events - New Dimensions for Survival (FRIENDS) registry: design of a prospective cohort study of patients with advanced peripheral artery disease The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Keo, H. H., S. Duval, I. Baumgartner, N. C. Oldenburg, M. R. Jaff, J. Goldman, J. M. Peacock, et al. 2013. “The FReedom from Ischemic Events - New Dimensions for Survival (FRIENDS) registry: design of a prospective cohort study of patients with advanced peripheral artery disease.” BMC Cardiovascular Disorders 13 (1): 120. doi:10.1186/1471-2261- 13-120. http://dx.doi.org/10.1186/1471-2261-13-120. Published Version doi:10.1186/1471-2261-13-120 Accessed February 19, 2015 3:19:42 PM EST Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879719 Terms of Use This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms- of-use#LAA (Article begins on next page) Keo et al. BMC Cardiovascular Disorders 2013, 13:120 http://www.biomedcentral.com/1471-2261/13/120 STUDY PROTOCOL Open Access The FReedom from Ischemic Events - New Dimensions for Survival (FRIENDS) registry: design of a prospective cohort study of patients with advanced peripheral artery disease Hong H Keo1, Sue Duval2, Iris Baumgartner3, Niki C Oldenburg2, Michael R Jaff4, JoAnne Goldman5, James M Peacock6, Alexander S Tretinyak5, Timothy D Henry5, Russell V Luepker7 and Alan T Hirsch2* Abstract Background: Advanced lower extremity peripheral artery disease (PAD), whether presenting as acute limb ischemia (ALI) or chronic critical limb ischemia (CLI), is associated with high rates of cardiovascular ischemic events, amputation, and death.
    [Show full text]
  • WO 2017/180086 Al 19 October 2017 (19.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/180086 Al 19 October 2017 (19.10.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/357 (2006.01) A61P 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/395 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/026876 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 11April 2016 ( 11.04.2016) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant: POP TEST ONCOLOGY LIMITED LIAB¬ (84) Designated States (unless otherwise indicated, for every ILITY COMPANY [US/US]; 36 Cecelia Avenue, Cliff- kind of regional protection available): ARIPO (BW, GH, side Park, NJ 070 10 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: ALTSCHUL, Randice, Lisa; 36 Cecelia Aven TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, ue, Cliffside Park, NJ 07010 (US).
    [Show full text]
  • Inflammation, Calcification, and Risk Prediction in Patients with Stable Cardiovascular Disease Cilie C
    Cilie C. van ‘t Klooster Beyond the scope of usual care Beyond the scope of in patients with stable cardiovascular disease cardiovascular with stable in patients Inflammation, calcification, and risk prediction and risk prediction calcification, Inflammation, Inflammation, calcification, and risk prediction in patients with stable cardiovascular disease Cilie C. van ‘t Klooster INFLAMMATION, CALCIFICATION, AND RISK PREDICTION IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE Beyond the scope of usual care Cilie Christina van ‘t Klooster Inflammation, calcification, and risk prediction in patients with stable cardiovascular disease Beyond the scope of usual care ISBN 978-94-6416-017-8 Cover design and layout by Evelien Jagtman, © evelienjagtman.com Printed by Ridderprint, www.ridderprint.nl © CC van ‘t Klooster, Utrecht, the Netherlands 2020 All rights reserved. No part of this dissertation may be reproduced or transmitted, in any form or by any means, without prior permission of the author. INFLAMMATION, CALCIFICATION, AND RISK PREDICTION IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE Beyond the scope of usual care Inflammatie, calcificatie en risicopredictie in patiënten met bestaande hart- en vaatziekte Buiten het kader van de reguliere zorg (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. H.R.B.M. Kummeling, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op donderdag 22 oktober 2020 des middags te 2.30 uur door Cilie Christina van ’t Klooster geboren op 9 maart 1991 te Haarlem Promotoren: Prof.dr. F.L.J. Visseren Prof.dr. Y. van der Graaf Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully acknowledged.
    [Show full text]
  • Concomitant Acute Ischemic Stroke and Upper Extremity Arterial Occlusion
    Journal of Clinical Medicine Article Concomitant Acute Ischemic Stroke and Upper Extremity Arterial Occlusion: Feasibility of Mechanical Thrombectomy of the Upper Limb Using Neurointerventional Devices and Techniques Dominik F. Vollherbst 1 , Christian Ulfert 1 , Volker Maus 2 , Timan Boujan 3 , Hans Henkes 4, Martin Bendszus 1 and Markus A. Möhlenbruch 2,* 1 Department of Neuroradiology, Heidelberg University Hospital, 69120 Heidelberg, Germany; [email protected] (D.F.V.); [email protected] (C.U.); [email protected] (M.B.) 2 Department of Radiology, Neuroradiology and Nuclear Medicine Ruhr-University Bochum, Knappschaftskrankenhaus, Bochum-Langendreer, 44892 Bochum, Germany; [email protected] 3 Department of Radiology, Hospital Ludwigshafen, 67063 Ludwigshafen, Germany; [email protected] 4 Neuroradiological Clinic, Klinikum Stuttgart, 70174 Stuttgart, Germany; [email protected] * Correspondence: [email protected] Citation: Vollherbst, D.F.; Ulfert, C.; Abstract: Background: Concomitant acute ischemic stroke (AIS) caused by large vessel occlusion Maus, V.; Boujan, T.; Henkes, H.; (LVO), and acute upper extremity arterial occlusion causing upper limb ischemia (ULI) is a rarely Bendszus, M.; Möhlenbruch, M.A. observed coincidence. The first-line treatment for AIS is mechanical thrombectomy (MT), with or Concomitant Acute Ischemic Stroke without additional intravenous thrombolysis, while there are different pharmacological, surgical and Upper Extremity Arterial and endovascular treatment options for an acute occlusion of the UL arteries. Here, we describe the Occlusion: Feasibility of Mechanical practicability, efficacy and safety of neurointerventional devices and techniques for MT of upper Thrombectomy of the Upper Limb extremity arterial occlusions. Materials and Methods: A retrospective analysis of prospectively Using Neurointerventional Devices collected patient databases from four neurovascular centers was performed.
    [Show full text]
  • Carotid Ultrasound Study
    Article Advanced Carotid Atherosclerosis and the Risk of Subsequent Major Cardiovascular Events: Carotid Ultrasound Study Elkilany, Galal E., Elmahal, Mohammed, Elsaady, Amenda, Singh, Jaipaul, Lohana, Petras, Gupta, Rajeev, Abdelrahman, Madian and Allah, Sherif Baath Available at http://clok.uclan.ac.uk/37361/ Elkilany, Galal E., Elmahal, Mohammed, Elsaady, Amenda, Singh, Jaipaul ORCID: 0000-0002-3200-3949, Lohana, Petras, Gupta, Rajeev, Abdelrahman, Madian and Allah, Sherif Baath (2021) Advanced Carotid Atherosclerosis and the Risk of Subsequent Major Cardiovascular Events: Carotid Ultrasound Study. Atherosclerosis: Open Access, 6 (2). It is advisable to refer to the publisher’s version if you intend to cite from the work. For more information about UCLan’s research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>. For information about Research generally at UCLan please go to http://www.uclan.ac.uk/research/ All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the policies page. CLoK Central Lancashire online Knowledge www.clok.uclan.ac.uk sis: O ero pe cl n s A o c r c Elkilany GEN, Atheroscler open access 2021, 6:2 e e h s t s A Atherosclerosis: Open Access ReviewResearch Article Article OpenOpen Access Acces Advanced Carotid Atherosclerosis and the Risk
    [Show full text]
  • Clopidogrel Versus Other Antiplatelet Agents in the Secondary Prevention
    Canadian Agency for Agence canadienne Drugs and Technologies des médicaments et des in Health technologies de la santé technology report Clopidogrel versus Other Antiplatelet Agents in HTA the Secondary Prevention of Vascular Events in Issue 123 Adults with Cerebrovascular Disease: Clinical December 2009* and Cost-Effectiveness Analyses *An amendment was made in August 2010 Supporting Informed Decisions Until April 2006, the Canadian Agency for Drugs and Technologies in Health (CADTH) was known as the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Publications can be requested from: CADTH 600-865 Carling Avenue Ottawa ON Canada K1S 5S8 Tel.: 613-226-2553 Fax: 613-226-5392 Email: [email protected] or downloaded from CADTH’s website: http://www.cadth.ca Cite as: Banerjee S, Brown A, Hutton B, McGahan L, Asakawa K, Clark M, Severn M, Cox JL, Sharma M. Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses. [Technology report number 123]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009. Production of this report is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Prince Edward Island, Saskatchewan, and theYukon. The Canadian Agency for Drugs and Technologies in Health takes sole responsibility for the final form and content of this report. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government. Reproduction of this document for non-commercial purposes is permitted provided appropriate credit is given to CADTH.
    [Show full text]